Back to Search
Start Over
Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism.
- Source :
- Gene Therapy; Jul2008, Vol. 15 Issue 13, p1007-1016, 10p, 1 Black and White Photograph, 5 Graphs
- Publication Year :
- 2008
-
Abstract
- A novel method for generating an antigen-specific cancer vaccine and immunotherapy has emerged using a DNA vaccine. However, antigen-presenting cells (APCs) have a limited life span, which hinders their long-term ability to prime antigen-specific T cells. Connective tissue growth factor (CTGF) has a role in cell survival. This study explored the intradermal administration of DNA encoding CTGF with a model tumor antigen, human papilloma virus type 16 E7. Mice vaccinated with CTGF/E7 DNA exhibited a dramatic increase in E7-specific CD4<superscript>+</superscript> and CD8<superscript>+</superscript> T-cell precursors. They also showed an impressive antitumor effect against E7-expressing tumors compared with mice vaccinated with the wild-type E7 DNA. The delivery of DNA encoding CTGF and E7 or CTGF alone could prolong the survival of transduced dendritic cells (DCs) in vivo. In addition, CTGF/E7-transduced DCs could enhance a higher number of E7-specific CD8<superscript>+</superscript> T cells than E7-transduced DCs. By prolonging the survival of APCs, DNA vaccine encoding CTGF linked to a tumor antigen represents an innovative approach to enhance DNA vaccine potency and holds promise for cancer prophylaxis and immunotherapy.Gene Therapy (2008) 15, 1007–1016; doi:10.1038/gt.2008.25; published online 20 March 2008 [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09697128
- Volume :
- 15
- Issue :
- 13
- Database :
- Complementary Index
- Journal :
- Gene Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 32626202
- Full Text :
- https://doi.org/10.1038/gt.2008.25